Renaissance Capital logo

Aratana Therapeutics postpones $51 million IPO

June 18, 2013

Aratana Therapeutics, which is developing medications for cats and dogs based on therapies for humans, postponed its IPO on Tuesday citing poor market conditions. The Kansas City, KS-based company was founded in 2010 and had expected to raise $51 million in its IPO by offering 4.3 million shares at a $11-$13 range. Stifel and Lazard Capital Markets were set to be the joint bookrunners on the deal.